Riskpilot← Back to searchSign inGet full accessPHARMAVAX AS
ASActiveOrg 926817108Jernbaneveien 4, 1400 SkiManufacture of pharmaceutical preparations · NACE 2120Est. 20210 employees
Revenue 2024
NOK 0
EBITDA margin
—
Equity ratio
-5.2%
Financial strength
Net profit 2024
NOK -139K
-54720% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -140K | — |
| Net profit | NOK -139K | -54720% |
| Total assets | NOK 1,1M | +63% |
| Equity | NOK -58K | -171% |
| Employees | 0 | — |
Legal name
PHARMAVAX AS
Org number
926817108
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29. mars 2021
Share capital
NOK 90 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling og markedsføring av legemidler og dertil hørende produkter.
Address
Jernbaneveien 4, 1400 Ski
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 |
| EBITDA | −7 | −2 | 0 | −140 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −7 | −2 | 0 | −140 |
| Net financials | −0 | 0 | 0 | 1 |
| Profit before tax | −7 | −2 | 0 | −139 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −7 | −2 | 0 | −139 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 236 | 382 | 681 | 1 109 |
| Equity | 83 | 81 | 81 | −58 |
| Long-term debt | 150 | 300 | 0 | 1 000 |
| Short-term debt | 3 | 0 | 600 | 167 |
| Total debt | 153 | 300 | 600 | 1 167 |
EBITDA margin
-13987800.0%
This company
15.8%
Market median
-88530480% vs market
20212024
Equity ratio
-5.2%
This company
38.2%
Market median
-114% vs market
20212024
Return on equity
-13928200.0%
This company
18.4%
Market median
-75696839% vs market
20212024
Net profit margin
-13928200.0%
This company
8.1%
Market median
-171953186% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
20.15×
This company
0.62×
Market median
-3150% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MG Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Wider Holding As
PHARMAVAX AS Board members of PHARMAVAX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Magnus Gunnar Paulsbo | Chief Executive Officer | 0 companies |
| Geir Ivar Westen | Chairman | 0 companies |
| Morten Gunnar Paulsbo | Board of Directors | 0 companies |